Belgian researchers found that micro-PET with either F-18 FDG, F-18 florbetapir or F-18 PBR111 all identified pathologic differences between mouse models with Alzheimer's disease that received BACE1 inhibitor treatment and controls, but only F-18 florbetapir detected treatment-induced reduction of amyloid-beta pathology among those with Alzheimer's. The findings in the Journal of Nuclear Medicine "clearly showed that accurate quantification of amyloid-beta tracers is critically important and that the non-specific uptake in the brain of subjects might be underestimated for some existing Alzheimer's tracers that have fast metabolization profiles," researchers said.
Study evaluates PET tracers in gauging Alzheimer's treatment efficacy
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.